SCHEMBL1612150

SCHEMBL1612150

O=C1N(CO)c2ccccc2C1(CO)c1cc2c(cc1O)OCO2

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 18/20 0.56
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007855 0.89 SCN9A (0.52) SCN9AALDH1A1MEN1KMT2A
SCHEMBL27707823 0.88 SCN9A (0.54) SCN9A
SCHEMBL281780 0.87 SCN9A (0.56) SCN9AKMT2A
SCHEMBL281748 0.87 SCN9A (0.63) SCN9A
SCHEMBL281825 0.86 SCN9A (0.77) SCN9A
SCHEMBL15314983 0.86 SCN9A (0.53) SCN9A
SCHEMBL281594 0.85 SCN9A (0.59) SCN9AKMT2A
SCHEMBL4597085 0.85 SCN9A (0.48) SCN9AALDH1A1MEN1KMT2A
SCHEMBL385208 0.84 SCN9A (0.43) SCN9AALDH1A1MEN1KMT2A
SCHEMBL14506505 0.84 ALDH1A1 (0.52) SCN9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9695185-B2 Synthetic methods for spiro-oxindole compounds XENON PHARMACEUTICALS INC. (CA) 2017-07-04 US disclosed
US-9695185-B2 Synthetic methods for spiro-oxindole compounds XENON PHARMACEUTICALS INC. (CA) 2017-07-04 US disclosed
US-9695185-B2 Synthetic methods for spiro-oxindole compounds XENON PHARMACEUTICALS INC. (CA) 2017-07-04 US disclosed
US-20160326184-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2016-11-10 US disclosed
US-20160326184-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2016-11-10 US disclosed
US-20160326184-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2016-11-10 US disclosed
US-9260446-B2 Synthetic methods for spiro-oxindole compounds XENON PHARMACEUTICALS INC. (CA) 2016-02-16 US disclosed
US-20140336390-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2014-11-13 US disclosed
US-20140336390-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2014-11-13 US disclosed
US-20140336390-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2014-11-13 US disclosed
US-8445696-B2 Synthetic methods for spiro-oxindole compounds XENON PHARMACEUTICALS INC. (CA) 2013-05-21 US disclosed
US-8445696-B2 Synthetic methods for spiro-oxindole compounds XENON PHARMACEUTICALS INC. (CA) 2013-05-21 US disclosed
US-8445696-B2 Synthetic methods for spiro-oxindole compounds XENON PHARMACEUTICALS INC. (CA) 2013-05-21 US disclosed
US-20130072686-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2013-03-21 US disclosed
US-20130072686-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2013-03-21 US disclosed
US-20130072686-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2013-03-21 US disclosed
WO-2011047174-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2011-04-21 WO disclosed
US-20110087027-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2011-04-14 US disclosed
US-20110087027-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2011-04-14 US disclosed
US-20110087027-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2011-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110087027-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS TRPV1, TRPV5, TRPV3 SCN9A 47/4885ALDH1A1 953/4885MEN1 2759/4885
US-20130072686-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS TRPV1, TRPV5, TRPV3 SCN9A 47/4885ALDH1A1 953/4885MEN1 2759/4885
US-20160326184-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS TRPV1, TRPV5, TRPV3 SCN9A 47/4885ALDH1A1 953/4885MEN1 2759/4885
US-20140336390-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS TRPV1, TRPV5, TRPV3 SCN9A 47/4885ALDH1A1 953/4885MEN1 2759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.